Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2020-06-29 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
2018年第一期员工持股计划锁定期届满的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the expiration of the lock-up period for an employee stock ownership plan (员工持股计划) of 瑞康医药集团股份有限公司. It details the stock purchase, lock-up period, and subsequent arrangements after the lock-up expiration. The document does not contain financial statements or detailed financial analysis but rather provides information about the status and plans related to the employee stock ownership plan. The document length is 2417 characters, which is relatively short and focused on a specific event rather than a comprehensive report. Therefore, it is best classified as a Regulatory Filing (RNS) because it is an official announcement about a corporate event that does not fit into other specific categories such as Annual Report, Interim Report, or Capital Update.
2020-06-29 Chinese
2017年面向合格投资者公开发行公司债券（第一期）、2018年面向合格投资者公开发行公司债券（第一期）2019年度定期受托管理事务报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2019年度定期受托管理事务报告" which translates to "2019 Annual Regular Trustee Management Affairs Report" related to bonds issued by 瑞康医药集团股份有限公司. It contains detailed information about bond issuance, bond management, financial status of the issuer, use of raised funds, bondholder meetings, credit ratings, and compliance with bond issuance regulations. The document is comprehensive and includes financial data and management oversight related to bond issuance and trustee duties. It is not an annual report of the company, nor an earnings release or a call transcript. It is a specialized report related to bond trustee management and bond issuance compliance. This type of document fits best under the category of Audit Report / Information (AR), as it is a standalone report on bond issuance management and compliance, including financial and operational oversight, but not a full annual report or earnings release. FY 2019
2020-06-16 Chinese
关于股东权益变动的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding a change in shareholder equity, specifically a reduction in shareholding by a significant shareholder (汇添富基金) that causes their ownership to fall below 5%. It details the number of shares before and after the change, the percentage ownership, and confirms that the change does not affect control of the company. The document references a "简式权益变动报告书" (Simplified Equity Change Report) and complies with regulatory requirements for shareholder disclosures. This type of document is a notification of a major shareholding change, fitting the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, not a full financial report or other types of filings.
2020-06-10 Chinese
公司债券2020年跟踪评级报告
Audit Report / Information Classification · 95% confidence The document is a detailed credit rating report for 瑞康医药集团股份有限公司 (Ruikang Pharmaceutical Group Co., Ltd.) issued by 联合信用评级有限公司 (United Credit Rating Co., Ltd.). It includes comprehensive financial data, credit ratings for the company and its bonds, detailed business and industry analysis, management changes, financial analysis, and future outlook. The document contains extensive financial figures, analysis of operating results, debt structure, and management commentary. It is not a brief announcement or a simple notice but a full report with substantive financial data and analysis. The presence of detailed financial statements, management discussion, and credit rating opinions indicates this is a standalone audit or credit rating report rather than an annual report or earnings release. It is not a regulatory filing or announcement of a report, nor is it a presentation or transcript. Therefore, the most appropriate classification is Audit Report / Information (AR). Q1 2020
2020-06-10 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled "简式权益变动报告书" which translates to "Simplified Equity Change Report". It details the changes in shareholding by 汇添富基金管理股份有限公司 in 瑞康医药集团股份有限公司, including specific share quantities before and after the change, the method of share reduction (竞价交易 - competitive bidding), dates, and percentages. It also references compliance with securities laws and disclosure obligations. The content is focused on reporting a change in major shareholding stakes, including past six months' trading activity and future plans. There is no financial performance data, audit information, or management discussion. This matches the definition of "Major Shareholding Notification" (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2020-06-10 Chinese
2019年年度股东大会决议的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as an announcement of the resolutions from the 2019 Annual General Meeting (AGM) of 瑞康医药集团股份有限公司. It details the voting results on various agenda items such as the 2019 board work report, annual report, financial reports, profit distribution plan, and supervisory board report. It also mentions the legal opinion confirming the validity of the meeting and voting process. The document is relatively short (2535 characters) and focuses on the official results of shareholder votes at the AGM. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2020-05-25 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.